Lung Cancer | Tumor

CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.

A Huge Heart for Patients With Lung Cancer

July 24th 2021

A patient with small cell lung cancer nominates writes about the woman who connected her to others with the same diagnosis.

Heart Failure May Increase Cancer Risk

July 23rd 2021

Patients with heart failure may have an increased incidence of cancer, which may be a result of similar risk factors including obesity and diabetes.

Rock Solid Care

July 23rd 2021

A cancer survivor writes about the oncologist who helped him conquer the fears and anxieties of cancer treatments.

FDA’s Rybrevant Approval ‘A Step Forward’ For Group of Patients With Non-Small Cell Lung Cancer

July 22nd 2021

The FDA’s recent approval of Rybrevant marks the first targeted therapy for a certain group of patients with non-small cell lung cancer, according to an expert at NYU Langone Health’s Perlmutter Cancer Center.

Peer Support Helps Patients Navigate Their Cancer Journey

July 18th 2021

Katie Brown, senior vice president of survivorship and support for LUNGevity Foundation, wrote about a program for patients to gain knowledge from survivors.

Passion Is Her Middle Name

July 11th 2021

"Jutta Becker does not wear a cape and she cannot fly, but she does soar," writes a colleague nominating Becker for the Lung Cancer Heroes® award.

Hope in Strength

July 10th 2021

Deborah Pickworth, who is living with stage 4 lung cancer, was nominated for the Lung Cancer Heroes® award for her impact in supporting and advocating for others with the disease.

Blue Sky High

July 10th 2021

A survivor with a nearly 10-year journey with lung cancer and ongoing treatment writes a poem about the emotional ups and downs of living with cancer.

World of Contributions

July 6th 2021

"Whereas scientific and organizational developments have been landmarks for Dr. Hirsch, his care for patients has always been in the center and, as a cancer survivor himself, he will always have patient care at the forefront."

Incredible Hero Without A Cape

July 3rd 2021

"Although Carolyn loved her role as a navigator, she realized she could help patients with lung cancer with a screening program to help with earlier detection."

The Journey to Personalized Cancer Vaccines

June 24th 2021

In this episode of the “CURE® Talks Cancer” podcast, Dr. Thomas Marron of the Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai in New York discusses the exciting future of cancer vaccines.

Molecular Testing in Thyroid Cancer: Interpreting Results

June 23rd 2021

Lori J. Wirth, MD, describes what information she looks for from results of molecular testing that help inform treatment for her patients with thyroid cancer.

Molecular Testing and Shared Decision-Making

June 23rd 2021

Andrea Ferris, of the LUNGevity Foundation, explains why shared decision-making is important when recommending molecular testing to patients with lung or thyroid cancer and highlights resources provided through her organization that support patients and health care professionals.

A ‘Turning Point’ for Metastatic NSCLC Treatment

June 22nd 2021

Patients with metastatic KRAS G12C mutated non-small cell lung cancer now have another treatment option if they previously failed at least one line of therapy.

Less Is More in Lung Cancer Treatment

June 17th 2021

Novel combo regimen reduces number of toxic treatments in patients with NSCLC.

Educating Patients About Biomarker Testing

June 16th 2021

Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.

The Emerging Role of Liquid Biopsies

June 16th 2021

Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

Best Practices When Testing With Comprehensive Genomic Profiling

June 9th 2021

Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.

Comprehensive Genomic Profiling in Lung and Thyroid Cancer

June 9th 2021

Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.

Opdivo-Yervoy Combination Could Benefit Patients with Non-Small Cell Lung Cancer

June 8th 2021

Combination of Opdivo and Yervoy had improved efficacy and durable response after four years in patients with advanced non-small cell lung cancer.

Novel Tyrosine Kinase Inhibitor Shows Promise for Metastatic Non-Small Cell Lung Cancer With Specific Genetic Mutation

June 8th 2021

Mobocertinib showed clinically meaningful benefits in patients with EGFR exon 20 insertion–positive metastatic non-small cell lung cancer with a manageable safety profile.

Alecensa Fails to Improve Survival in Lung Cancer Subset

June 7th 2021

In a final analysis of a study examining the effectiveness of Alecensa compared to Xalkori in patients with non-small cell lung cancer, the Alecensa-treated group did not achieve better survival outcomes.

Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer

June 7th 2021

The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Aumolertinib Improves Survival in Advanced Non-Small Cell Lung Cancer

June 7th 2021

Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

June 6th 2021

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Gavreto ‘Very Well Tolerated’ in RET Fusion-Positive Non-Small Cell Lung Cancer

June 5th 2021

Findings demonstrated that Gavreto could clinically benefit those with RET fusion-positive non-small cell lung cancer, including those who are treatment naïve.

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

May 28th 2021

The agency approved Lumakras, the first targeted therapy for patients with non-small cell lung cancer and a KRAS G12C mutation, whose disease progressed after one systemic therapy.

FDA Approves Rybrevant for Certain Group of Patients with Non-Small Cell Lung Cancer

May 21st 2021

The decision from the Food and Drug Administration marks the first approval of a targeted treatment option for adults with non-small cell lung cancer whose tumors harbor a specific genetic mutation.

Treatment Considerations for TIL Therapy in NSCLC

May 18th 2021

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

Clinical Trials of TIL Therapy in NSCLC

May 18th 2021

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

NEXT PAGE
PREVIOUS PAGE